0

7-ABF

7-ABF

7-ABF (7-Aminoflunitrazepam)

 

PRODUCT DETAILS TABLE

Specification Details
Brand Biosynlab
Product Name 7-ABF (7-Aminoflunitrazepam)
IUPAC Name 7-amino-5-(2-fluorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
CAS Number 34041-84-4
Molecular Formula C₁₆H₁₄FN₃O
Molecular Weight 283.30 g/mol
Chemical Class Benzodiazepine metabolite / 1,4-benzodiazepin-2-one
Purity ≥99.0% (HPLC Verified)
Appearance White to pale yellow crystalline powder
Melting Point 225-230°C (decomposition)
Solubility Soluble in DMSO, methanol; sparingly soluble in ethanol
Storage -20°C, desiccated, away from light
Packaging Amber glass vial with PTFE seal
Quantities 100mg, 250mg, 500mg, 1g, 5g, bulk
Analysis COA, NMR, MS, FTIR included
Shipping Express courier, tracked, discreet
Regions USA, UK, Germany, Netherlands, EU, Canada

PRODUCT PAGE DESCRIPTION (870+ Words)

Introduction

7-ABF (7-Aminoflunitrazepam) represents a critical benzodiazepine metabolite that serves as an essential analytical standard in forensic toxicology, clinical pharmacology, and drug-facilitated sexual assault (DFSA) investigation protocols. As the primary pharmacologically active metabolite of flunitrazepam (Rohypnol), 7-aminoflunitrazepam provides crucial insights into nitroreduction metabolic pathways and serves as a key target analyte in forensic screening panels. Biosynlab delivers pharmaceutical-grade 7-ABF with certified ≥99.0% purity, supporting cutting-edge research across USA, United Kingdom, European Union, and international forensic and clinical laboratories.

The metabolic biotransformation of flunitrazepam’s 7-nitro group to the amino functionality represents a major pathway mediated by hepatic CYP450 enzymes, particularly CYP3A4 and CYP2C19. This reduction produces 7-aminoflunitrazepam, which exhibits significant pharmacological activity and extended detection windows in biological matrices compared to the parent compound. Forensic laboratories in London, Berlin, Amsterdam, New York, and Los Angeles rely on Biosynlab 7-ABF for quantitative confirmation in DFSA cases, workplace drug testing, and therapeutic drug monitoring applications where flunitrazepam use is suspected.

Showing the single result